Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

43.61 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A High-Yield Dividend Stock Worth Considering
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high 5.18% dividend yield with strong profitability and reasonable valuation, making it a compelling choice for dividend investors. 
Via Chartmill
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Via The Motley Fool
Topics Intellectual Property Retirement
1 Cash-Producing Stock to Own for Decades and 2 to Think Twice About
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
AnaptysBio's Arthritis Drug Matches Top Therapies In Phase 2 Trial, Analyst Sees Turning Point
Rosnilimab met key RA trial goals, with sustained clinical responses and safety benefits, prompting an analyst upgrade and price target hike to $38. 
Via Benzinga
Why BioNTech Stock Soared Today
Bristol Myers Squibb just agreed to shower BioNTech with cash. 
Via The Motley Fool
Bristol Myers Inks $11 Billion Licensing Pact With BioNTech For Bispecific Cancer Drug
BioNTech and Bristol Myers Squibb will co-develop BNT327 for solid tumors in a $1.5 billion deal with potential milestones totaling up to $7.6 billion. 
Via Benzinga
Bristol Myers To Pay Up To $11.1B To BioNTech To Co-Develop, Commercialize Investigational Cancer Drug
BMS will pay BioNTech $1.5 billion in an upfront payment in the second quarter and $2 billion in non-contingent anniversary payments through 2028. 
Via Stocktwits
Topics Government
BioNTech and Bristol Myers Squibb Announce Global Strategic Partnership to Co-Develop and Co-Commercialize Next-generation Bispecific Antibody Candidate BNT327 Broadly for Multiple Solid Tumor Types
From Bristol Myers Squibb
Via Business Wire
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) – A Potentially Undervalued Dividend Stock
BRISTOL-MYERS SQUIBB (NYSE:BMY) offers a high dividend yield, strong profitability, and an undervalued stock price, making it a candidate for value investors. 
Via Chartmill
1 S&P 500 Stock for Long-Term Investors and 2 to Brush Off
While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural... 
Via StockStory
Topics Stocks
Bristol Myers Squibb to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Receives European Commission Approval for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb to Present Data at ASCO® 2025 Highlighting Differentiated Research Platform of Oncology Treatments and Innovative Research Pipeline
From Bristol Myers Squibb
Via Business Wire
1 Safe-and-Steady Stock to Own for Decades and 2 to Think Twice About
A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on higher-reward opportunities elsewhere. 
Via StockStory
Bristol Myers Squibb to Participate in the Bernstein 41st Annual Strategic Decisions Conference
From Bristol Myers Squibb
Via Business Wire
Prediction: These Could Be the Best-Performing Healthcare Stocks Through 2030
Via The Motley Fool
Topics Economy Law Enforcement
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Options Corner: Political Turmoil Sets Up A Contrarian Call Spread For Bristol-Myers Squibb
Although the Trump administration's healthcare policies pose risks for Bristol-Myers Squibb, the chaos opens a contrarian door for BMY stock. 
Via Benzinga
Topics Government
3 Stocks That Will Profit From Trump's Drug Price Cut
Trump's EO aims to lower US drug prices by using leverage of public programs (like Medicare) to force accountability. Big pharma may be hit hardest. 
Via Benzinga
Topics Government
Bristol Myers Squibb Receives European Commission Approval for Perioperative Regimen of Neoadjuvant Opdivo® (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo for Resectable, High-Risk Non-Small Cell Lung Cancer with PD-L1 Expression ≥1%
From Bristol Myers Squibb
Via Business Wire
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) - A High-Yield Dividend Stock Worth Considering
BRISTOL-MYERS SQUIBB CO (NYSE:BMY) offers a high 5.29% dividend yield with strong growth and profitability, making it a solid pick for income investors. 
Via Chartmill
What's going on in today's session: S&P500 movers
Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
What Most-Favored-Nation Status Could Mean for Pharmaceutical Stocks
Via The Motley Fool
Topics Economy Government
Stay informed with the top movers within the S&P500 index on Wednesday.
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Wednesday as we examine the latest happenings in today's session. 
Via Chartmill
Sanofi To Navigate Tariff Impact With $20 Billion In Spending Through 2030
Sanofi plans $20 billion US investment by 2030 to expand R&D and manufacturing, aiming to boost medicine production and job creation across states. 
Via Benzinga
CMS Expands Medicare Drug Price Talks To Part B Meds In 2026 Shake Up
CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public comments due by June 26. 
Via Benzinga
Bristol-Myers Squibb Strikes $350 Million Deal To End Hawaii's Plavix Lawsuit
Bristol-Myers Squibb will pay $350 million to settle Hawaii's lawsuit over Plavix marketing practices, ending claims without admitting wrongdoing and avoiding trial. 
Via Benzinga
Topics Lawsuit
Top Biotech Halozyme Undercuts Its Breakout On Bad Medicare News
It's biggest product will be up for price negotiations under the Inflation Reduction Act much sooner than expected. 
Via Investor's Business Daily
Topics Economy Government
Market Monitor News May 12 ( NRG Energy, Amazon, Meta Platforms UP - CVS Health DOWN)
Wall Street surges sharply as US-China tariff cuts drive tech stocks higher; pharma sector gains on new Trump drug pricing initiative. 
Via Chartmill
Topics Government World Trade
Merck, Pfizer, Eli Lilly Stocks Rebound As Trump Targets Drug Costs With New Executive Order
The U.S. President said that Big Pharma would either voluntarily abide by this principle or the federal government will use its power to ensure the U.S. pays the same price as other countries. 
Via Stocktwits
Topics Government
< Previous 1 2 3 4 5 6 7 8 9
...
81 82 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.